{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T18:50:54Z","timestamp":1694631054754},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1007\/s11864-003-0011-1","type":"journal-article","created":{"date-parts":[[2007,6,28]],"date-time":"2007-06-28T08:41:17Z","timestamp":1183020077000},"page":"105-110","source":"Crossref","is-referenced-by-count":1,"title":["Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer"],"prefix":"10.1007","volume":"4","author":[{"given":"Elizabeth","family":"Swisher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"11_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/00005792-199805000-00006","volume":"77","author":"LC Brody","year":"1998","unstructured":"Brody LC, Biesecker BB: Breast cancer susceptibility genes. BRCA1 and BRCA2. Medicine (Baltimore) 1998, 77:208\u2013226.","journal-title":"Medicine (Baltimore)"},{"key":"11_CR2","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#","volume":"71","author":"P Watson","year":"1993","unstructured":"Watson P, Lynch HT: Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993, 71:677\u2013685.","journal-title":"Cancer"},{"key":"11_CR3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L","volume":"81","author":"M Aarnio","year":"1999","unstructured":"Aarnio M, Sankila R, Pukkala E, et al.: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999, 81:214\u2013218.","journal-title":"Int J Cancer"},{"key":"11_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ijc.2910640613","volume":"64","author":"M Aarnio","year":"1995","unstructured":"Aarnio M, Mecklin JP, Aaltonen LA, et al.: Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995, 64:430\u2013433.","journal-title":"Int J Cancer"},{"key":"11_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJM200107263450401","volume":"345","author":"B Modan","year":"2001","unstructured":"Modan B, Hartge P, Hirsh-Yechezkel G, et al.: Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345:235\u2013240. A population study of Israeli women with ovarian cancer reporting that parity reduced ovarian cancer risk in women with BRCA1 and BRCA2 mutations.","journal-title":"N Engl J Med"},{"key":"11_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1006\/gyno.1994.1332","volume":"55","author":"EL Trimble","year":"1994","unstructured":"Trimble EL: The NIH consensus conference on ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994, 55:S1-S3.","journal-title":"Gynecol Oncol"},{"key":"11_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1006\/gyno.1994.1065","volume":"52","author":"T Bourne","year":"1994","unstructured":"Bourne T, Campbell S, Reynolds K, et al.: The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer. Gynecol Oncol 1994, 52:379\u2013385.","journal-title":"Gynecol Oncol"},{"key":"11_CR8","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1034\/j.1600-0412.1999.781013.x","volume":"78","author":"A Dorum","year":"1999","unstructured":"Dorum A, Heimdal K, Lovslett K, et al.: Prospectively detected cancer in familial breast\/ovarian cancer screening. Acta Obstet Gynecol Scand 1999, 78:906\u2013911.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"11_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1006\/gyno.2000.5816","volume":"77","author":"JR van Nagell","year":"2000","unstructured":"van Nagell JR Jr, DePriest PD, Reedy MB, et al.: The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000, 77:350\u2013356.","journal-title":"Gynecol Oncol"},{"key":"11_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1001\/jama.277.12.997","volume":"277","author":"W Burke","year":"1997","unstructured":"Burke W, Daly M, Garber J, et al.: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997, 277:997\u20131003.","journal-title":"JAMA"},{"key":"11_CR11","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0002-9378(99)70663-0","volume":"180","author":"BY Karlan","year":"1999","unstructured":"Karlan BY, Baldwin RL, Lopez-Luevanos E, et al.: Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 1999, 180:917\u2013928. A study describing the occurrence of advanced stage peritoneal cancer among high-risk women being screened for ovarian cancer, revealing a limitation of screening in women at risk for familial ovarian cancer.","journal-title":"Am J Obstet Gynecol"},{"key":"11_CR12","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1136\/bmj.306.6884.1030","volume":"306","author":"I Jacobs","year":"1993","unstructured":"Jacobs I, Davies AP, Bridges J, et al.: Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993, 306:1030\u20131034.","journal-title":"BMJ"},{"key":"11_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1006\/gyno.1997.4686","volume":"65","author":"Robinson G Erlick","year":"1997","unstructured":"Erlick Robinson G, Rosen BP, Bradley LN, et al.: Psychological impact of screening for familial ovarian cancer: reactions to initial assessment. Gynecol Oncol 1997, 65:197\u2013205.","journal-title":"Gynecol Oncol"},{"key":"11_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/ijc.2910280602","volume":"28","author":"NS Weiss","year":"1981","unstructured":"Weiss NS, Lyon JL, Liff JM, et al.: Incidence of ovarian cancer in relation to the use of oral contraceptives. Int J Cancer 1981, 28:669\u2013671.","journal-title":"Int J Cancer"},{"key":"11_CR15","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1002\/1097-0142(19811001)48:7<1684::AID-CNCR2820480735>3.0.CO;2-A","volume":"48","author":"WC Willett","year":"1981","unstructured":"Willett WC, Bain C, Hennekens CH, et al.: Oral contraceptives and risk of ovarian cancer. Cancer 1981, 48:1684\u20131687.","journal-title":"Cancer"},{"key":"11_CR16","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/oxfordjournals.aje.a117055","volume":"139","author":"L Rosenberg","year":"1994","unstructured":"Rosenberg L, Palmer JR, Zauber AG, et al.: A casecontrol study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994, 139:654\u2013661.","journal-title":"Am J Epidemiol"},{"key":"11_CR17","doi-asserted-by":"crossref","unstructured":"Oral contraceptive use and the risk of ovarian cancer. The Centers for Disease Control Cancer and Steroid Hormone study.JAMA 1983, 249:1596-1599.","DOI":"10.1001\/jama.249.12.1596"},{"key":"11_CR18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1056\/NEJM198703123161102","volume":"316","author":"M Zatyka","year":"1987","unstructured":"Zatyka M: The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987, 316:650\u2013655.","journal-title":"N Engl J Med"},{"key":"11_CR19","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/bjc.1995.260","volume":"71","author":"MP Vessey","year":"1995","unstructured":"Vessey MP, Painter R: Endometrial and ovarian cancer and oral contraceptives: findings in a large cohort study. Br J Cancer 1995, 71:1340\u20131342.","journal-title":"Br J Cancer"},{"key":"11_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJM199808133390702","volume":"339","author":"SA Narod","year":"1998","unstructured":"Narod SA, Risch H, Moslehi R, et al.: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998, 339:424\u2013428.","journal-title":"N Engl J Med"},{"key":"11_CR21","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(00)04642-0","volume":"357","author":"SA Narod","year":"2001","unstructured":"Narod SA, Sun P, Ghadirian P, et al.: Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case control study. Lancet 2001, 357:1467\u20131470. A case control study showing a reduction in risk for ovarian cancer from use of oral contraceptives among BRCA mutation carriers and from bilateral tubal ligation in BRCA1 mutation carriers.","journal-title":"Lancet"},{"key":"11_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/0090-8258(92)90147-B","volume":"47","author":"GM Kemp","year":"1992","unstructured":"Kemp GM, Hsiu JG, Andrews MC: Papillary peritoneal carcinomatosis after prophylactic oophorectomy. Gynecol Oncol 1992, 47:395\u2013397.","journal-title":"Gynecol Oncol"},{"key":"11_CR23","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1002\/1097-0142(19930501)71:9<2751::AID-CNCR2820710911>3.0.CO;2-J","volume":"71","author":"MS Piver","year":"1993","unstructured":"Piver MS, Jishi MF, Tsukada Y, et al.: Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993, 71:2751\u20132755.","journal-title":"Cancer"},{"key":"11_CR24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/jnci\/90.11.841","volume":"90","author":"JO Schorge","year":"1998","unstructured":"Schorge JO, Muto MG, Welch WR, et al.: Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 1998, 90:841\u2013845.","journal-title":"J Natl Cancer Inst"},{"key":"11_CR25","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa020119","volume":"346","author":"ND Kauff","year":"2002","unstructured":"Kauff ND, Satagopan JM, Robson ME, et al.: Riskreducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002, 346:1609\u20131615.","journal-title":"N Engl J Med"},{"key":"11_CR26","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1056\/NEJM200209263471317","volume":"347","author":"SH Zhuang","year":"2002","unstructured":"Zhuang SH, Leonard GD, Swain SM: Oophorectomy in carriers of BRCA mutations. N Engl J Med 2002, 347:1037\u20131040.","journal-title":"N Engl J Med"},{"key":"11_CR27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1056\/NEJM200209263471317","volume":"347","author":"GA Whitfield","year":"2002","unstructured":"Whitfield GA: Oophorectomy in carriers of BRCA mutations. N Engl J Med 2002, 347:1037\u20131040.","journal-title":"N Engl J Med"},{"key":"11_CR28","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"TR Rebbeck","year":"2002","unstructured":"Rebbeck TR, Lynch HT, Neuhausen SL, et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346:1616\u20131622. A landmark study indicating the strong effect of prophylactic oophorectomy on reducing the risk of ovarian and breast cancer in women with BRCA1 and BRCA2 mutations.","journal-title":"N Engl J Med"},{"key":"11_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1006\/gyno.2000.6003","volume":"79","author":"R Goshen","year":"2000","unstructured":"Goshen R, Chu W, Elit L, et al.: Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?\n                           Gynecol Oncol 2000, 79:477\u2013481.","journal-title":"Gynecol Oncol"},{"key":"11_CR30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1006\/gyno.2000.6082","volume":"80","author":"DA Levine","year":"2001","unstructured":"Levine DA, Lin O, Barakat RR, et al.: Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 2001, 80:395\u2013398.","journal-title":"Gynecol Oncol"},{"key":"11_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/hmg\/6.1.105","volume":"6","author":"MG Dunlop","year":"1997","unstructured":"Dunlop MG, Farrington SM, Carothers AD, et al.: Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997, 6:105\u2013110.","journal-title":"Hum Mol Genet"},{"key":"11_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1006\/gyno.2002.6779","volume":"87","author":"K Leeper","year":"2002","unstructured":"Leeper K, Garcia R, Swisher E, et al.: Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002, 87:52\u201356. This study identified occult cancers of the fallopian tube, peritoneum, and ovary in 17% of high-risk women undergoing prophylactic surgery.","journal-title":"Gynecol Oncol"},{"key":"11_CR33","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1200\/JCO.2000.18.14.2728","volume":"18","author":"KH Lu","year":"2000","unstructured":"Lu KH, Garber JE, Cramer DW, et al.: Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000, 18:2728\u20132732. Describes the identification of occult cancers in 12% of women with BRCA1 and BRCA2 mutations undergoing prophylactic surgery.","journal-title":"J Clin Oncol"},{"key":"11_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1006\/gyno.2002.6638","volume":"85","author":"TJ Colgan","year":"2002","unstructured":"Colgan TJ, Boerner SL, Murphy J, et al.: Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol 2002, 85:397\u2013403.","journal-title":"Gynecol Oncol"},{"key":"11_CR35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1006\/gyno.2000.6071","volume":"80","author":"PJ Paley","year":"2001","unstructured":"Paley PJ, Swisher EM, Garcia RL, et al.: Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 2001, 80:176\u2013180.","journal-title":"Gynecol Oncol"},{"key":"11_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/00000478-200202000-00003","volume":"26","author":"SN Agoff","year":"2002","unstructured":"Agoff SN, Mendelin JE, Grieco VS, et al.: Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol 2002, 26:171\u2013178.","journal-title":"Am J Surg Pathol"},{"key":"11_CR37","doi-asserted-by":"crossref","unstructured":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial.JAMA 2002, 288:321-333.","DOI":"10.1001\/jama.288.3.321"},{"key":"11_CR38","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/jnci\/91.17.1475","volume":"91","author":"TR Rebbeck","year":"1999","unstructured":"Rebbeck TR, Levin AM, Eisen A, et al.: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999, 91:1475\u20131479.","journal-title":"J Natl Cancer Inst"},{"key":"11_CR39","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.1998.16.3.979","volume":"16","author":"VR Grann","year":"1998","unstructured":"Grann VR, Panageas KS, Whang W, et al.: Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 1998, 16:979\u2013985.","journal-title":"J Clin Oncol"},{"key":"11_CR40","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.2002.08.035","volume":"20","author":"MS van Roosmalen","year":"2002","unstructured":"van Roosmalen MS, Verhoef LC, Stalmeier PF, et al.: Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. J Clin Oncol 2002, 20:2092\u20132100.","journal-title":"J Clin Oncol"},{"key":"11_CR41","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1001\/jama.270.23.2813","volume":"270","author":"SE Hankinson","year":"1993","unstructured":"Hankinson SE, Hunter DJ, Colditz GA, et al.: Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993, 270:2813\u20132818.","journal-title":"JAMA"},{"key":"11_CR42","first-page":"1","volume":"21","author":"TL Cornelison","year":"1997","unstructured":"Cornelison TL, Natarajan N, Piver MS, et al.: Tubal ligation and the risk of ovarian carcinoma. Cancer Detect Prev 1997, 21:1\u20136.","journal-title":"Cancer Detect Prev"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-003-0011-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-003-0011-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-003-0011-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-003-0011-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T13:22:28Z","timestamp":1652620948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-003-0011-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1007\/s11864-003-0011-1","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4]]}}}